AKBA
Price
$2.29
Change
-$0.00 (-0.00%)
Updated
Jan 30, 04:59 PM (EDT)
Capitalization
501.82M
40 days until earnings call
MLTX
Price
$47.25
Change
+$1.19 (+2.58%)
Updated
Jan 30, 04:59 PM (EDT)
Capitalization
2.9B
52 days until earnings call
Ad is loading...

AKBA vs MLTX

Header iconAKBA vs MLTX Comparison
Open Charts AKBA vs MLTXBanner chart's image
Akebia Therapeutics
Price$2.29
Change-$0.00 (-0.00%)
Volume$18.03K
Capitalization501.82M
MoonLake Immunotherapeutics
Price$47.25
Change+$1.19 (+2.58%)
Volume$1.79K
Capitalization2.9B
AKBA vs MLTX Comparison Chart
Loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBA vs. MLTX commentary
Jan 31, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBA is a StrongBuy and MLTX is a Buy.

Ad is loading...
COMPARISON
Comparison
Jan 31, 2025
Stock price -- (AKBA: $2.30 vs. MLTX: $47.12)
Brand notoriety: AKBA and MLTX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBA: 47% vs. MLTX: 90%
Market capitalization -- AKBA: $501.82M vs. MLTX: $2.9B
AKBA [@Biotechnology] is valued at $501.82M. MLTX’s [@Biotechnology] market capitalization is $2.9B. The market cap for tickers in the [@Biotechnology] industry ranges from $379.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.47B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBA’s FA Score shows that 0 FA rating(s) are green whileMLTX’s FA Score has 0 green FA rating(s).

  • AKBA’s FA Score: 0 green, 5 red.
  • MLTX’s FA Score: 0 green, 5 red.
According to our system of comparison, AKBA is a better buy in the long-term than MLTX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBA’s TA Score shows that 4 TA indicator(s) are bullish while MLTX’s TA Score has 5 bullish TA indicator(s).

  • AKBA’s TA Score: 4 bullish, 5 bearish.
  • MLTX’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, MLTX is a better buy in the short-term than AKBA.

Price Growth

AKBA (@Biotechnology) experienced а -3.77% price change this week, while MLTX (@Biotechnology) price change was +0.51% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.11%. For the same industry, the average monthly price growth was +1.05%, and the average quarterly price growth was +4.49%.

Reported Earning Dates

AKBA is expected to report earnings on May 12, 2025.

MLTX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-1.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MLTX($2.91B) has a higher market cap than AKBA($502M). AKBA YTD gains are higher at: 21.053 vs. MLTX (-12.982). AKBA has higher annual earnings (EBITDA): 4.3M vs. MLTX (-108.45M). MLTX has more cash in the bank: 494M vs. AKBA (34M). MLTX has less debt than AKBA: MLTX (3.69M) vs AKBA (48.6M). AKBA has higher revenues than MLTX: AKBA (170M) vs MLTX (0).
AKBAMLTXAKBA / MLTX
Capitalization502M2.91B17%
EBITDA4.3M-108.45M-4%
Gain YTD21.053-12.982-162%
P/E RatioN/AN/A-
Revenue170M0-
Total Cash34M494M7%
Total Debt48.6M3.69M1,318%
FUNDAMENTALS RATINGS
AKBA: Fundamental Ratings
AKBA
OUTLOOK RATING
1..100
28
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
37
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKBAMLTX
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
67%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bullish Trend 3 days ago
73%
Momentum
ODDS (%)
Bullish Trend 3 days ago
78%
Bearish Trend 3 days ago
59%
MACD
ODDS (%)
Bullish Trend 3 days ago
83%
Bullish Trend 3 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
55%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
52%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 5 days ago
70%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
83%
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
54%
View a ticker or compare two or three
Ad is loading...
AKBA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MLTX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
AWSAX16.190.15
+0.94%
Invesco Global Core Equity A
RYIIX153.99N/A
N/A
Rydex Internet Inv
LGLFX51.29N/A
N/A
Lord Abbett Growth Leaders F
GRSRX51.66N/A
N/A
Cohen & Steers Global Realty R
NEEIX64.14N/A
N/A
Needham Growth Institutional

AKBA and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKBA has been loosely correlated with ABOS. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if AKBA jumps, then ABOS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBA
1D Price
Change %
AKBA100%
N/A
ABOS - AKBA
43%
Loosely correlated
-0.64%
KOD - AKBA
40%
Loosely correlated
+0.74%
BEAM - AKBA
40%
Loosely correlated
+5.29%
FBIO - AKBA
40%
Loosely correlated
+2.30%
ABCL - AKBA
40%
Loosely correlated
+0.94%
More

MLTX and

Correlation & Price change

A.I.dvisor indicates that over the last year, MLTX has been loosely correlated with XENE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if MLTX jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MLTX
1D Price
Change %
MLTX100%
+2.30%
XENE - MLTX
37%
Loosely correlated
+0.70%
EDIT - MLTX
37%
Loosely correlated
+2.24%
CRNX - MLTX
37%
Loosely correlated
+2.23%
AKBA - MLTX
36%
Loosely correlated
N/A
RGNX - MLTX
36%
Loosely correlated
+5.05%
More